These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Lee JJA; Saito T; Duddy W; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539 [TBL] [Abstract][Full Text] [Related]
3. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy. Wilton SD; Fletcher S Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827 [TBL] [Abstract][Full Text] [Related]
4. Single Exon Skipping Can Address a Multi-Exon Duplication in the Dystrophin Gene. Greer K; Johnsen R; Nevo Y; Fellig Y; Fletcher S; Wilton SD Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630425 [TBL] [Abstract][Full Text] [Related]
5. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838 [TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript. Wilton SD; Fletcher S Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057 [TBL] [Abstract][Full Text] [Related]
12. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
13. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856 [TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091 [TBL] [Abstract][Full Text] [Related]
15. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies. Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801 [TBL] [Abstract][Full Text] [Related]
16. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient. Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540 [TBL] [Abstract][Full Text] [Related]
17. Exon skipping and Duchenne muscular dystrophy: hope, hype and how feasible? Wilton SD; Fletcher S Neurol India; 2008; 56(3):254-62. PubMed ID: 18974551 [TBL] [Abstract][Full Text] [Related]
18. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle. Popplewell LJ; Graham IR; Malerba A; Dickson G Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027 [TBL] [Abstract][Full Text] [Related]
19. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping. Madden HR; Fletcher S; Davis MR; Wilton SD Hum Mutat; 2009 Jan; 30(1):22-8. PubMed ID: 18570328 [TBL] [Abstract][Full Text] [Related]
20. Contributions of Japanese patients to development of antisense therapy for DMD. Matsuo M; Takeshima Y; Nishio H Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]